Associations between circulating sex steroid hormones and cognition in normal elderly women

Objective: To provide exploratory analyses of associations between levels of several sex hormones and cognitive performance in elderly women. Background: Sex steroid hormones are implicated in the cognitive processes of the adult brain. Comparing cognitive performance across or between conditions associated with different hormone levels, such as phases of the menstrual cycle, surgical menopause, and estrogen replacement therapy suggests conditions with higher levels of estrogen are associated with better verbal memory and possibly worse visuospatial ability. Method: The authors measured circulating sex hormone levels in 39 highly educated, nondemented, predominantly white elderly women. Levels were correlated with neuropsychological performance, controlling for age, education, frequency of prior testing, use of estrogen replacement, and depression. Results: High estradiol levels were associated with better delayed verbal memory and retrieval efficiency, whereas low levels were associated with better immediate and delayed visual memory. Levels of testosterone were related positively to verbal fluency. Levels of progesterone and androstenedione were unrelated to cognitive performance. Conclusions: Both estrogen and testosterone showed associations with cognitive performance. Estrogen may enhance, and depress, specific cognitive skills.

[1]  R. Pascuzzi.  Myasthenia gravis and Lambert-Eaton syndrome. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  E. Kaplan,et al.  Boston Naming Test , 2001 .

[4]  K. Yaffe,et al.  Serum Estrogen Levels, Cognitive Performance, and Risk of Cognitive Decline in Older Community Women , 1998, Journal of the American Geriatrics Society.

[5]  D. Sanders.  3,4‐Diaminopyridine (DAP) in the Treatment of Lambert‐Eaton Myasthenic Syndrome (LEMS) a , 1998, Annals of the New York Academy of Sciences.

[6]  R. Barohn,et al.  Reliability Testing of the Quantitative Myasthenia Gravis Score a , 1998, Annals of the New York Academy of Sciences.

[7]  J. Rommens,et al.  Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy , 1998, Nature Genetics.

[8]  S. W. Davies,et al.  Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? , 1998, The Lancet.

[9]  S. Resnick,et al.  Estrogen replacement therapy and longitudinal decline in visual memory , 1997, Neurology.

[10]  S. Carson,et al.  Effect of Postmenopausal Estrogen Replacement on Circulating Androgens , 1997, Obstetrics and gynecology.

[11]  H. Reichmann,et al.  Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency , 1997, Neuromuscular Disorders.

[12]  M. Pericak-Vance,et al.  Confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13 in American families suggests the existence of a second causal mutation , 1997, Neuromuscular Disorders.

[13]  B. Eymard,et al.  Genealogical study of oculopharyngeal muscular dystrophy in France , 1997, Neuromuscular Disorders.

[14]  J. Bouchard,et al.  Recent studies on oculopharyngeal muscular dystrophy in Québec , 1997, Neuromuscular Disorders.

[15]  A. Helbling-Leclerc,et al.  Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy , 1997, Neuromuscular Disorders.

[16]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[17]  K. Fischbeck,et al.  Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 , 1997, Neuron.

[18]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[19]  D. Clapham,et al.  Ion channels--basic science and clinical disease. , 1997, The New England journal of medicine.

[20]  J. Heckmatt,et al.  A double blind cross over trial of theophylline prophylaxis for sleep hypoxaemia in Duchenne muscular dystrophy , 1997, Neuromuscular Disorders.

[21]  F. Muntoni,et al.  Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies , 1997, Neuromuscular Disorders.

[22]  M. Rose,et al.  A rapidly progressive adolescent‐onset oculopharyngeal somatic syndrome with rimmed vacuoles in two siblings , 1997, Annals of neurology.

[23]  S. Servidei.  Mitochondrial encephalomyopathies: Gene mutation , 1996, Neuromuscular Disorders.

[24]  B. Anlar,et al.  3,4-Diaminopyridine in Childhood Myasthenia: Double-Blind, Placebo-Controlled Trial , 1996, Journal of child neurology.

[25]  F. Fazekas,et al.  Estrogen Replacement Therapy In Older Women: A Neuropsychological And Brain MRI Study , 1996, Journal of the American Geriatrics Society.

[26]  W. Engel,et al.  New advances in the understanding of sporadic inclusion‐body myositis and hereditary inclusion‐body myopathies , 1995, Current opinion in rheumatology.

[27]  C. Allen,et al.  Contributions to Neuropsychological Assessment , 1995 .

[28]  J. Weissenbach,et al.  The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac α and β myosin heavy chain genes on chromosome 14q11.2−q13 , 1995 .

[29]  E. Wahle,et al.  Immunodetection of poly(A) binding protein II in the cell nucleus. , 1994, Experimental cell research.

[30]  D. Sanders,et al.  Repetitive nerve stimulation studies in the Lambert–Eaton myasthenic syndrome , 1994, Muscle & nerve.

[31]  F. Naftolin.  Brain aromatization of androgens. , 1994, The Journal of reproductive medicine.

[32]  S. Paul,et al.  Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. , 1993, Neuroendocrinology.

[33]  I. Rosén,et al.  Practical aspects of 3,4‐diaminopyridine treatment of the Lambert‐Eaton myasthenic syndrome , 1993, Acta neurologica Scandinavica.

[34]  J. Howard,et al.  3,4‐Diaminopyridine in Lambert‐Eaton Myasthenic Syndrome and Myasthenia Gravis a , 1993, Annals of the New York Academy of Sciences.

[35]  D P Salmon,et al.  Effects of Age, Gender and Education on Selected Neuropsychological Tests in an Elderly Community Cohort , 1993, Journal of the American Geriatrics Society.

[36]  J. Halperin,et al.  Neuropathic findings in oculopharyngeal muscular dystrophy. A report of seven cases and a review of the literature. , 1993, Archives of neurology.

[37]  C. Longcope,et al.  Androgen and estrogen dynamics: relationships with age, weight, and menopausal status. , 1993, The Journal of clinical endocrinology and metabolism.

[38]  B. Sherwin,et al.  Effects of estrogen on memory function in surgically menopausal women , 1992, Psychoneuroendocrinology.

[39]  B. Sherwin,et al.  Variations in memory function and sex steroid hormones across the menstrual cycle , 1992, Psychoneuroendocrinology.

[40]  J. Palace,et al.  3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[41]  E. Wahle.  A novel poly(A)-binding protein acts as a specificity factor in the second phase of messenger RNA polyadenylation , 1991, Cell.

[42]  Elizabeth Hampson,et al.  Estrogen-related variations in human spatial and articulatory-motor skills , 1990, Psychoneuroendocrinology.

[43]  Elizabeth Hampson,et al.  Variations in sex-related cognitive abilities across the menstrual cycle , 1990, Brain and Cognition.

[44]  J. Daube,et al.  3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. , 1989, The New England journal of medicine.

[45]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[46]  C. V. van Donselaar,et al.  Reliability of the diagnosis of a first seizure , 1989, Neurology.

[47]  B. Sherwin,et al.  Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women , 1988, Psychoneuroendocrinology.

[48]  R. Lobo,et al.  A randomized comparison of nonoral estradiol delivery in postmenopausal women. , 1988, American journal of obstetrics and gynecology.

[49]  R. Greenlee,et al.  Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. , 1987, The New England journal of medicine.

[50]  I. Rosén,et al.  Novel drug of choice in Eaton-Lambert syndrome. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[51]  R. Katzman.,et al.  Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. , 1983, The American journal of psychiatry.

[52]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[53]  D. Perl,et al.  Oculopharyngeal muscular dystrophy An autopsied case from the french-canadian kindred , 1982, Journal of the Neurological Sciences.

[54]  K. Krause,et al.  An autopsy study of a familial oculopharyngeal muscular dystrophy (OPMD) with distal spread and neurogenic involvement , 1981, Muscle & nerve.

[55]  B. J. Davidson,et al.  Changes in Circulating Steroids with Aging in Postmenopausal Women , 1981, Obstetrics and gynecology.

[56]  D. Mishell,et al.  A double-antibody radioimmunoassay for serum progesterone using progesterone-3-(o-carboxymethyl)oximino-[125l]-iodo-histamine as radioligand , 1978, Steroids.

[57]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[58]  P. Tsairis.  Muscle Biopsy: A Modern Approach , 1974 .

[59]  Sue Healey,et al.  Oculopharyngeal Muscular Dystrophy , 1963, British medical journal.

[60]  E. Lambert,et al.  Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. , 1957, Journal of the American Medical Association.

[61]  E. Taylor.  PROGRESSIVE VAGUS-GLOSSOPHARYNGEAL PARALYSIS WITH PTOSIS. A CONTRIBUTION TO THE GROUP OF FAMILY, DISEASES , 1915 .

[62]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[63]  M. Fardeau,et al.  Nuclear inclusions in oculopharyngeal dystrophy. , 1980, Acta neuropathologica.